The Pharma Data

MARCH 15, 2022

For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc. to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience. Nicholas Galakatos, Ph.D.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

pharmaphorum

DECEMBER 15, 2022

Boehringer Ingelheim taps new head of medicine. As we reported 4th November, Boehringer Ingelheim brought on former Novartis neurosciences head Lykke Hinsch Gylvin (pictured below) into the role of head of medicine and chief medical officer. Read on for a round-up of some of the biggest moves that crossed our desks. More CEO shakeups.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

The Pharma Data

OCTOBER 20, 2020

“As a long-time watcher of TLC, I have observed improvements on all fronts and am impressed by the ripening pipeline and the efficiency of the development process of bringing life-changing medicines to patients.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

The Pharma Data

JANUARY 24, 2021

This is the first time this level of durability has been achieved in a Phase III study of an injectable eye medicine for nAMD. It has been more than 15 years since a medicine with a new mechanism of action has been approved to treat nAMD. Faricimab is the first bispecific antibody designed for the eye. About faricimab.

Antibody 40

Antibody Medicine Drug Delivery Development 40

The Pharma Data

JANUARY 17, 2021

At Gilead he led the organization in the successful filing of numerous New Drug Applications (NDAs) and supplemental label updates across multiple therapeutic areas. Before this, he held various positions at Duke University Medical Center.

Life Science 40

Life Science Drug Delivery Engineer Drugs 40

Delveinsight

JANUARY 22, 2021

Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved shortly. Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases, designed to leverage the natural interaction between IgG antibodies and the recycling receptor FcRn.

Marketing 65

Marketing Drugs Antibody Compliance 65

Roots Analysis

MARCH 9, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry.

Manufacturing 52

Manufacturing Marketing Contract Manufacturing Protein 52

The Pharma Data

MAY 15, 2023

“If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 7 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye. Review by other regulatory authorities is ongoing.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

JUNE 26, 2021

The PDS Marketing Authorisation Application has also been validated by the European Medicines Agency and is currently under review. Faricimab is the first investigational bispecific antibody designed for the eye. Portal is an extension study evaluating the long-term safety and efficacy of PDS in nAMD.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. 1 4 About Vabysmo ® ( faricimab ) Vabysmo is the first bispecific antibody approved for the eye.

Antibody 40

Antibody In-Vitro Development Trials 40

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

JANUARY 6, 2021

Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found h e re.

Medicine 52

Medicine Antibody Protein In-Vitro 52

Drug Discovery World

JANUARY 17, 2024

The company aims to advance platform technologies including chemoproteomics, molecular glue and covalent drug discovery, high-throughput screening, protein and antibody engineering, gene and epigenetic editing, gene and cell therapies, drug delivery, and data science.

Drugs 52

Drugs Drug Delivery Life Science Gene 52

Drug Discovery World

APRIL 29, 2024

The last couple of months has seen a number of changes in senior roles in the drug discovery sector. He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

The Pharma Data

JANUARY 15, 2021

The submission was also reviewed under Project Orbis, an initiative of the FDA Oncology Center of Excellence, which provides a framework for concurrent submission and review of oncology medicine applications among international regulatory agencies. About Darzalex Faspro® In August 2012, Janssen Biotech, Inc.

FDA Approval 52

FDA Approval Production Research Doctors 52

Roots Analysis

MARCH 24, 2022

Personalized medicine or precision medicine is an emerging field with the potential to develop novel and efficacious custom-based clinical therapies, wherein metabolomics holds a potential role. Metabolomics has already assisted in informed decision making for biomarker discovery and toxicology testing. Our Social Media Platform.

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

Roots Analysis

OCTOBER 22, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.

RNA 40

RNA Protein Genetics Gene Expression 40

Pharmaceutical Technology

APRIL 24, 2023

This intersection will be remembered as one of the most significant achievements in science and medicine”. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drug delivery. Lipid nanoparticle drug delivery was in the spotlight during the Covid-19 pandemic.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

The Pharma Data

MAY 5, 2021

New Scottish Agency Would Ensure Supply Of Cost-Effective Drugs ( Pink Sheet ). India approves Roche/Regeneron antibody cocktail to treat COVID-19 ( Reuters ). Adagio offers first peek at Covid-19 antibody data, with preventative numbers that may rival mRNA vaccines ( Endpoints ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

Pharmaceutical Technology

APRIL 16, 2023

But with the advent of injection site absorption enhancers, drug delivery device innovations, as well as the recent primary container options, the practical subcutaneous self-administration of large-volume parenterals is becoming possible. National Library of Medicine – Silicone Oil Induced Aggregation of Proteins 4.

Protein 130

Protein Containment Drug Delivery Drugs 130